| Literature DB >> 29626596 |
Hiroki Mizuno1, Akinari Sekine2, Masahiko Oguro2, Yoichi Oshima2, Masahiro Kawada2, Keiichi Sumida2, Masayuki Yamanouchi2, Noriko Hayami2, Tatsuya Suwabe2, Rikako Hiramatsu2, Eiko Hasegawa2, Junichi Hoshino2, Naoki Sawa2, Takashi Fujii3, Kenmei Takaichi4, Kenichi Ohashi5, Yoshifumi Ubara4.
Abstract
An 84-year-old Japanese man was admitted due to anasarca, thrombocytopenia, systemic inflammation, and progressive renal insufficiency, resistance to diuretics, glucocorticoid therapy, and plasma exchange. Renal biopsy showed diffuse endocapillary proliferation and mesangiolysis without any immune deposits. Tocilizumab suppressed systemic inflammation, resulting in improvement of anasarca and renal dysfunction, but thrombocytopenia persisted and platelet-associated IgG antibody was elevated. Although romiplostim was effective for thrombocytopenia, the patient died of aspiration pneumonia after cerebral hemorrhage. Autopsy showed hyaline vascular-type Castleman disease-like lymphadenopathy and reticulin myelofibrosis with an increase of megakaryocytes. Renal finding showed that endocapillary injury improved, and collapsed glomeruli were noted. This patient fitted the criteria for TAFRO (thrombocytopenia [T], anasarca [A], fever [F], reticulin myelofibrosis [R], and organomegaly [O]) syndrome. The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient.Entities:
Keywords: Multicentric Castleman disease; TAFRO syndrome; Thrombocytopenia; Thrombotic microangiopathy; Tocilizumab
Mesh:
Substances:
Year: 2018 PMID: 29626596 DOI: 10.1016/j.humpath.2018.03.021
Source DB: PubMed Journal: Hum Pathol ISSN: 0046-8177 Impact factor: 3.466